See the DrugPatentWatch profile for tigecycline

Based on the information available, there are several practices that can help prevent the reduced potency of tigecycline. Tigecycline is an antibiotic used to treat various bacterial infections, and its effectiveness can be compromised due to several factors. Here are some practices that can help prevent the reduced potency of tigecycline:

1. Proper Dosage: Administering the correct dosage of tigecycline is crucial in preventing its reduced potency. According to the prescribing information, the recommended dosage of tigecycline is 100 mg initially, followed by 50 mg every 12 hours [1]. Deviating from the recommended dosage can lead to the development of antibiotic resistance.
2. Duration of Therapy: The duration of tigecycline therapy should be as short as possible to prevent the development of antibiotic resistance. The prescribing information recommends a duration of therapy of 5-14 days, depending on the patient's response to treatment [1].
3. Combination Therapy: Combining tigecycline with other antibiotics can help prevent the development of antibiotic resistance. According to a study published in the Journal of Antimicrobial Chemotherapy, combining tigecycline with other antibiotics can help prevent the development of antibiotic resistance [2].
4. Appropriate Use: Tigecycline should only be used to treat infections caused by susceptible bacteria. Using tigecycline to treat infections caused by bacteria that are not susceptible to the drug can lead to the development of antibiotic resistance [1].
5. Monitoring: Monitoring the patient's response to tigecycline therapy is crucial in preventing the development of antibiotic resistance. If the patient is not responding to tigecycline therapy, it may be necessary to switch to a different antibiotic [1].

In summary, administering the correct dosage, keeping the duration of therapy as short as possible, combining tigecycline with other antibiotics, using tigecycline appropriately, and monitoring the patient's response to therapy can help prevent the reduced potency of tigecycline.

Sources:
[1] Tigecycline Prescribing Information. Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
[2] Rolain, J. M., Gutierrez, B., Trecuprier-Bertrand, S., Bebear, C., & Rolain, J. (2008). In vitro activities of tigecycline alone or in combination with other antibiotics against clinical isolates of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 62(2), 353-357.
[3] DrugPatentWatch.com - Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>